Vanda Pharmaceuticals ( VNDA ) says senior VP and CCO Robert Repella is out, effective January 1. Repella is entitled to a list of severance benefits, which can be reviewed in the 8-K . 1 comment!
Overweight at Piper. Price target is $20. Amgen ( AMGN ) initiated at Overweight at Piper. Price target is $143. Vanda ( VNDA ) started at Overweight at Piper. Price target is $21. Piper initiates Pharmacyclics ( PCYC ) at Overweight. Price target
By EnhydrisPECorp : The last two years or so have seen the entire biotech sector catch fire. The SPDR Biotech ETF ( XBI ) is up over 45% in that time, after only appreciating 26% in the six years prior. The sentiment change around biotechs appears to be linked to the record number of FDA approvals
process can still come up with the entirely unexpected. Yesterday's overwhelmingly positive adcom vote for Vanda Pharmaceuticals ' sleep disorder project tasimelteon is a case in point. The FDA's likely approval - despite questions over
been a good week for shares of Vanda Pharmaceuticals ( VNDA ) as both FDA staff and Ad Com ..... carry over into regular trading, VNDA will have risen nearly 120% since ..... September 3 are just 8% . See also: VNDA enjoys " love-fest " at Ad Com
Top Gainers, as of 5:15 p.m.: VNDA +19.3% . CADX +10.4% . TTS +8.3% . WPX +6.3% . A +4.9% . Top Losers, as of 5:15 p.m: SRPT -9.5% . ONVO -7.4% . FU -4.7% . YNDX -4.2% . MITL -3.9% . 2 comments!
Vanda Pharmaceuticals ( VNDA ) will resume trading at 4:40pm ET. Previous : Vanda scores clean sweep at Ad Com Post your comment!
The news couldn't have been better for Vanda Pharmaceuticals ( VNDA ), with an FDA panel voting positively by overwhelming ..... Never seen a company so dominate proceedings." VNDA shares remain halted. Previous : FDA votes 10
An FDA panel votes 10-1 that Vanda Pharmaceuticals ' ( VNDA ) clinical endpoints used in the tasimelteon development program are appropriate to support an indication in non-24 sleep disorder. Post your comment!
following Fanapt's approval, raising doubt about management's view of Vanda's future, in our opinion. Vanda Pharmaceuticals focuses on the development and commercialization of therapies for central nervous system disorders. Its lead